Learn about the latest treatments that uncover serious conditions, signal disease severity, or change a mortality outlook.
The FDA has approved dozens of new therapeutics in the past year, as well as new indications for existing drugs. As a result, medications appearing on applicant profiles may point to conditions, disease severity, and mortality implications that weren’t apparent before.
Join Hayley Vrchota to learn what their presence implies and how to determine the likely severity of conditions being treated, so you can underwrite with confidence and speed.
Topics covered
- Using Irix Irix Medical Data to determine when GLP-1s are being prescribed for obstructive sleep apnea
- The first agent specifically approved for MASH and how previous prescription patterns may indicate a condition associated with significantly elevated mortality
- A new CFTR modulator that gives some people with cystic fibrosis access to a much more effective therapy (and a realistic hope of much longer lifespan)
- A new HIV PrEP drug uses the same active ingredient as one prescribed to people already infected. Learn to identify the specific indication in order to understand its mortality implications
- Novel treatments for serious conditions including schizophrenia and resistant hypertension
Who should attend
Underwriters, medical directors, and other clinical professionals who make life insurance underwriting decisions will benefit from a review of the latest clinical and data science used to interpret the risk implications of these new therapeutics.
Hayley Vrchota PharmD, CTTS
Clinical Consultant
Kyle Schimek PharmD, BCPS
Manager, Clinical Services
